3SHUKRY M, MILLER JA. Update on dexmedetomidine: use in nonintubated patients requiring sedation for surgical procedures [J]. Ther Clin Risk Manag,2010,6:111 -121.
6BEEMER GH, BJORKSTEN AR, CRANKSHAW DP. Effect of body build on the clearance of atraeurium: implication for drug dosing[ J ]. Anesth Analg, 1993,76 (6) : 1296 - 1303.
4Iannuzzi M, Iannuzzi E, Rossi F, et al. Relationship between Bispectral Index, electroencephalographic state entropy and effectsite EC50 for propofol at different clinical endpoints [J]. Br J Anaesth, 2005, 94(4): 492-495.
5Glass P S, Bloom M, Kearse L, et al. Bispectral analysis measures sedation and memory effects of propofol, midazolam,isoflurane, and alfentanil in healthy volunteers [J ]. Anesthesiology, 1997, 86 (4): 836-847.
6Calvo R, Telletxea S, Leal N, et al. Influence of formulation on propofol pharmacokinetics and pharmacodynamics in anesthetized patients [ J ]. Acta Anaesthesiol Scand, 2004, 48 (8) : 1038-1048.
7Mourisse L, Booij L. Bispectral index detects period of cerebral hypoperfusion during cardiopulmonary bypass [J]. J Cardiothorac Vasc Anesth, 2003, 17( 1 ) : 76-78.
8BHANA N,GOA K L,MCCLELLAN K J.Dexmedetomidine[J].Drugs,2000,59:263-268.
9ANTTILA M,PENTTILA J,HELMINEN A,et al.Bioavailability of dexmedetomidine after extravascular doses in healthy subjects[J].Br J Clin pharmacol,2003,56(6):691-693.
10MAZE M,SCARFINI C,CAVALIERE F.New agents for sedation in the intensive care unit[J].Crit Care Clin,2001,17:881-897.
